Ann: Half Yearly Report and Accounts, page-19

the first article was from a couple of years ago, so you can presume the number of trials will be significant higher in 2019/2020. I think it's also part of the reason Imugene expanded into eastern Europe and Asia. Also the bottom article, less than 5% of cancer patients participate in trials.

"There are too many experimental cancer drugs in too many clinical trials, and not enough patients to  test them on. The logjam is caused partly by companies hoping to rush profitable new cancer drugs   to market, and partly by the nature of these therapies, which can be spectacularly effective but only in select patients.


https://www.nytimes.com/2017/08/12/...als-encounter-a-problem-too-few-patients.html

https://www.nytimes.com/2019/06/20/well/live/the-need-for-clinical-trial-navigators.html